<div id="readability-page-1"><div>NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Praxis Precision Medicines, Inc. (“Praxis” or the “Company”) (NASDAQ: PRAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Praxis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On August 4, 2025, Praxis issued a press release reporting its financial results for the second quarter of 2025. Among other items, Praxis disclosed mid-stage study results for its anti-seizure medication vormatrigine. The Company reported that 36 of 61 patients experienced treatment-emergent adverse events, and that almost one in four participants discontinued the study. On this news, Praxis’s stock price fell $3.00 per share, or 5.55%, to close at $51.09 per share on August 4, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETXlOeU0zTURnM09UTXlJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ETXlOeU0zTURnM09UTXlJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTRjNWYyNzQtYmI5Yy00Y2Q0LWI4ODctOWNlNDg3MmRjODVkLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NTRjNWYyNzQtYmI5Yy00Y2Q0LWI4ODctOWNlNDg3MmRjODVkLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

PRAX

Pomerantz 律师事务所正在代表 Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX）的投资者调查有关该公司及其高管潜在证券欺诈的索赔。这一调查是由于 Praxis 最近的财务报告揭示其抗癫痫药物的中期研究中出现不利事件，导致股价下跌 5.55%。鼓励投资者联系 Pomerantz 以获取有关加入集体诉讼的更多信息

投资者警报：Pomerantz 律师事务所正在代表 Praxis Precision Medicines, Inc.的投资者调查索赔 - PRAX